Related Experiment Videos
Color vision tests for early detection of antiepileptic drug toxicity
Abstract:
A previous suggestion that antiepileptic drugs may induce color vision deficiencies prompted us to examine whether color vision deficiencies may occur at lower drug serum concentrations than those associated with symptoms of neurotoxicity. Eighty patients presenting with epilepsy received monotherapies of valproic acid, phenytoin, or carbamazepine; 18 patients did not receive antiepileptic drug therapy. Color vision was tested by the Farnsworth-Munsell 100-hue test, spectral sensitivity, and the newly developed tritan screening plates. Patients treated with phenytoin or carbamazepine developed blue-yellow color vision deficiencies. In contrast, patients exposed to valproic acid or receiving no drug treatment showed normal color vision. There was a significant correlation (p < 0.0001) between signs of neurotoxicity induced by phenytoin or carbamazepine and blue-yellow color vision deficiencies. In contrast, we found no correlation between these signs of neurotoxicity and the drug serum concentrations (p = 0.0637). Color vision testing in epileptic patients treated with phenytoin or carbamazepine appears to be a sensitive method for early detection and monitoring of clinical neurotoxicity.
Insights
Certain antiepileptic drugs like phenytoin and carbamazepine can cause blue-yellow color vision deficiencies in epilepsy patients. This visual impairment may signal neurotoxicity before other symptoms appear.
Area of Science:
- Neuroscience
- Ophthalmology
- Clinical Pharmacology
Background:
- Antiepileptic drugs (AEDs) are crucial for epilepsy management.
- Previous research suggested a link between AEDs and color vision deficiencies.
- The relationship between AED serum concentrations, neurotoxicity, and visual disturbances requires further investigation.
Purpose of the Study:
- To investigate if color vision deficiencies occur at lower serum concentrations of AEDs than neurotoxic symptoms.
- To determine which AEDs are associated with color vision deficits.
- To assess the utility of color vision testing for early neurotoxicity detection in epilepsy patients.
Main Methods:
- Eighty epilepsy patients on monotherapy (valproic acid, phenytoin, or carbamazepine) were studied.
- Eighteen epilepsy patients not on AEDs served as a control group.
- Color vision was assessed using the Farnsworth-Munsell 100-hue test, spectral sensitivity, and tritan screening plates.
Main Results:
- Phenytoin and carbamazepine treatments were associated with blue-yellow color vision deficiencies.
- Valproic acid and no AED treatment groups showed normal color vision.
- A significant correlation was found between neurotoxicity signs and blue-yellow color vision deficits for phenytoin and carbamazepine, but not with drug serum concentrations.
Conclusions:
- Blue-yellow color vision deficiencies are linked to phenytoin and carbamazepine therapy in epilepsy patients.
- Color vision testing can serve as a sensitive indicator for early detection of neurotoxicity associated with these AEDs.
- This visual assessment may precede other clinical signs of neurotoxicity, aiding in patient monitoring.